Myriad Expands IP Portfolio with Exclusive License for Pancreatic Cancer Gene Patents | GenomeWeb

By Turna Ray

Myriad Genetics is planning to launch a new diagnostic test for early detection of pancreatic cancer next year based on the assessment of PALB2 gene mutations, as well as mutations in the BRCA2 gene and p16 genes.

Myriad said last week that it has obtained from Johns Hopkins University an exclusive, worldwide license to patents covering mutations in the PALB2 gene, which have been shown to confer an increased risk for pancreatic cancer in those who carry the gene variants.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: gene flow between ancient chimpanzees and bonobos, and more.

A startup wants to match customers to wine based on their DNA and one critic calls the idea 'silly,' Stat News reports.

Researchers trace the origins of brown rats using genetic analysis to China, the New York Times reports.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.